Skip Navigation

JNCI Monographs 2005 2005(34):40-43; doi:10.1093/jncimonographs/lgi015
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Blumenfeld, Z.
Right arrow Articles by Eckman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blumenfeld, Z.
Right arrow Articles by Eckman, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

2005 © Oxford University Press

Preservation of Fertility and Ovarian Function and Minimization of Chemotherapy-Induced Gonadotoxicity in Young Women by GnRH-a

Z. Blumenfeld, A. Eckman

Affiliation of authors: Reproductive Endocrinology, Rambam Medical Center, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel 31096

Correspondence to: Zeev Blumenfeld, MD, Reproductive Endocrinology and Infertility Section, Department of Obstetrics and Gynecology, Technion-Faculty of Medicine, Rambam Medical Center, Haifa 31096 Israel (e-mail: bzeev{at}techunix.technion.ac.il).

Improved long-term survival in young women with lymphoma and leukemia has increased attention to the preservation of their future fertility. We have attempted to minimize the gonadotoxic effect of chemotherapy by cotreatment with a GnRH agonist analog, inducing a temporary prepubertal milieu. Our prospective clinical case series includes 92 women with lymphoma, aged 15–40 years, 10 with leukemia and 18 undergoing chemotherapeutic treatments for nonmalignant autoimmune diseases. Depot D-TRP6-GnRH-a was injected monthly from before the initiation of chemotherapy until its conclusion, for up to 6 months. We used 82 similarly treated patients with lymphoma not given GnRH-a as a comparison group. All but five of the surviving evaluable patients with GnRH-a/chemotherapy cotreatment resumed spontaneous ovulation and menses or conceived, whereas 53% of the patients in the comparison group experienced premature ovarian failure (P<.01). Mechanisms to explain this apparent chemoprotective effect are discussed, and the work of other investigators in this area is reviewed.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
I. Demeestere, P. Simon, S. Emiliani, A. Delbaere, and Y. Englert
Fertility Preservation: Successful Transplantation of Cryopreserved Ovarian Tissue in a Young Patient Previously Treated for Hodgkin's Disease
Oncologist, December 1, 2007; 12(12): 1437 - 1442.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
V. Vernaeve, D. Bodri, M. Colodron, R. Vidal, M. Durban, and O. Coll
Endometrial receptivity after oocyte donation in recipients with a history of chemotherapy and/or radiotherapy
Hum. Reprod., November 1, 2007; 22(11): 2863 - 2867.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
Z. Blumenfeld
How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries
Oncologist, September 1, 2007; 12(9): 1044 - 1054.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
Z. Blumenfeld, M. B. Arush, and T. Zuckerman
Spontaneous pregnancy and normal delivery after repeated autologous bone marrow transplantation and GnRH agonist treatment
Hum. Reprod., August 1, 2007; 22(8): 2346 - 2346.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.